Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3271-3280 Newer>

The Motley Fool November 13, 2006 Jack Uldrich	Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment.
The Motley Fool November 13, 2006 Brian Lawler	Biovail Is Getting Cheap One of the drugmaker's products could face generic competition in the next year. Investors, take note.
The Motley Fool November 10, 2006 Brian Lawler	Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note.
The Motley Fool November 10, 2006 Brian Lawler	Watson Doesn't Wow Investors The generic drug developer made a $2 billion buyout of smaller competitor Andrx and finally closed the deal this quarter. Investors, take note.
The Motley Fool November 9, 2006 Brian Lawler	Noven Might Be in a Purple Patch Investors in Noven shares might as well pay most of their attention to Shire, because as long as Daytrana does well, so too will Noven.
The Motley Fool November 9, 2006 Karl Thiel	The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note.
The Motley Fool November 9, 2006 Mike Norman	CVS-Caremark Not So Hard to Swallow Huge demographic and policy trends are likely to make this match a winner. Why did investors sell CVS?
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool November 8, 2006 Rich Duprey	BioLase's Reason to Smile Dental laser maker narrows loss and inks distribution deal to boost sales. The stock is a little rich at its current prices, though. Investors, take note.
The Motley Fool November 8, 2006 Michael P. Cecil	CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm.
<Older 3271-3280 Newer> Return to current articles.